Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second-quarter ...

Cellebrite DI announced its half-year 2025 results, reporting revenue of US$220.83 million, a turnaround to net income of US$36.88 million, and the appointment of Thomas E. Hogan as CEO, following his ...

Cellebrite (CLBT) boasts strong growth potential with robust financials, digital forensics leadership, and a durable moat.

Q2 2025 Earnings Call Transcript August 14, 2025 Cellebrite DI Ltd. beats earnings expectations. Reported EPS is $0.12, ...

Detailed price information for Cellebrite Di Ltd (CLBT-Q) from The Globe and Mail including charting and trades.

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat.com ...

Thomas E. Hogan Named CEO ARR grew 21% to $418.9 million; Revenue grew 18% to $113.3 million Net income of $19.5 million supports non-GAAP net income of $30.8 million and adjusted EBITDA of $27.9 ...

Earlier this year, Cellebrite DI Ltd. (NASDAQ:CLBT) underwent an independent review and received a FedRAMP High Ready status. Now, with the US Department of Justice as its sponsor, the company ...

Cellebrite DI ( ($CLBT) ) has provided an update. Cellebrite DI Ltd. has released its unaudited consolidated financial statements for the six ...

Stay up to date on how Cellebrite DI Ltd (CLBT:XNAS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.